| HRA006493
(Controlled Access)
|
Multiple combinational immunotherapy regimens are currently being explored in clinical trials. While preclinical studies have provided insights into the mechanisms of these regimens, their efficacy and impact on the tumor microenvironment (TME) in patients are not fully understood. Understanding the dynamics of the TME during different combinational therapies is crucial for optimizing immunotherapy approaches, particularly for patients who do not respond to treatment. Here, we performed single-cell RNA-sequencing (scRNA-seq) analysis on tumor samples from patients diagnosed with non-small cell lung cancer (NSCLC). These samples include paired pre-treatment biopsy and post-neoadjuvant treatment samples with PD-1 inhibitors in combination with either chemotherapy or anti-VEGFA therapy. By integrating the transcriptomic profiles of more than1 million cells, we identified shared and distinct mechanisms within the TME in response to different therapy regimens. |
